Hao Li

Zhexin Zhang, Leqi Lei, Junxiao Yang et al.

As AI models are increasingly deployed across diverse real-world scenarios, ensuring their safety remains a critical yet underexplored challenge. While substantial efforts have been made to evaluate and enhance AI safety, the lack of a standardized framework and comprehensive toolkit poses significant obstacles to systematic research and practical adoption. To bridge this gap, we introduce AISafetyLab, a unified framework and toolkit that integrates representative attack, defense, and evaluation methodologies for AI safety. AISafetyLab features an intuitive interface that enables developers to seamlessly apply various techniques while maintaining a well-structured and extensible codebase for future advancements. Additionally, we conduct empirical studies on Vicuna, analyzing different attack and defense strategies to provide valuable insights into their comparative effectiveness. To facilitate ongoing research and development in AI safety, AISafetyLab is publicly available at https://github.com/thu-coai/AISafetyLab, and we are committed to its continuous maintenance and improvement.

De-Xing Huang, Xiao-Hu Zhou, Mei-Jiang Gui et al.

Iodinated contrast agents are widely utilized in numerous interventional procedures, yet posing substantial health risks to patients. This paper presents CAS-GAN, a novel GAN framework that serves as a "virtual contrast agent" to synthesize X-ray angiographies via disentanglement representation learning and vessel semantic guidance, thereby reducing the reliance on iodinated contrast agents during interventional procedures. Specifically, our approach disentangles X-ray angiographies into background and vessel components, leveraging medical prior knowledge. A specialized predictor then learns to map the interrelationships between these components. Additionally, a vessel semantic-guided generator and a corresponding loss function are introduced to enhance the visual fidelity of generated images. Experimental results on the XCAD dataset demonstrate the state-of-the-art performance of our CAS-GAN, achieving a FID of 5.87 and a MMD of 0.016. These promising results highlight CAS-GAN's potential for clinical applications.